Comparative Pharmacology
Head-to-head clinical analysis: LOXITANE C versus PROLIXIN DECANOATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOXITANE C versus PROLIXIN DECANOATE.
LOXITANE C vs PROLIXIN DECANOATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loxapine, a dibenzoxazepine antipsychotic, acts primarily by blocking dopamine D2 receptors in the brain. It also exhibits affinity for serotonin 5-HT2A receptors, alpha-adrenergic, histaminergic, and muscarinic receptors, contributing to its antipsychotic and sedative effects.
Fluphenazine decanoate is a long-acting phenothiazine antipsychotic that blocks dopamine D1 and D2 receptors in the brain, particularly in the mesolimbic and mesocortical pathways, with higher affinity for D2 receptors. It also exhibits alpha-adrenergic blocking and anticholinergic activity.
10 mg orally twice daily initially; may increase by 10 mg/day every 3–4 days; usual therapeutic range 60–100 mg/day; maximum 250 mg/day.
Fluphenazine decanoate initial dose 12.5-25 mg IM or SC every 1-4 weeks; maintenance dose 12.5-50 mg every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life is 4-8 hours (mean 6 hours). Clinical context: Requires multiple daily dosing; stable plasma levels achieved by second day.
Terminal elimination half-life approximately 14 days (range 6-25 days) after intramuscular injection, reflecting slow release from the oily depot; allows for every 2-4 week dosing.
Approximately 70% renal (mainly as conjugated metabolites, <1% unchanged), 30% fecal via biliary excretion.
Renal (approximately 50% as conjugated metabolites, <1% unchanged) and fecal (approximately 30%, primarily via bile).
Category C
Category C
Antipsychotic
Antipsychotic